BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 27003392)

  • 1. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
    Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
    Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial.
    Nabati M; Janbabai G; Esmailian J; Yazdani J
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):233-241. PubMed ID: 30599756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
    Cardinale D; Colombo A; Sandri MT; Lamantia G; Colombo N; Civelli M; Martinelli G; Veglia F; Fiorentini C; Cipolla CM
    Circulation; 2006 Dec; 114(23):2474-81. PubMed ID: 17101852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
    Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
    Gupta V; Kumar Singh S; Agrawal V; Bali Singh T
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27308. PubMed ID: 30009543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
    Kalay N; Basar E; Ozdogru I; Er O; Cetinkaya Y; Dogan A; Inanc T; Oguzhan A; Eryol NK; Topsakal R; Ergin A
    J Am Coll Cardiol; 2006 Dec; 48(11):2258-62. PubMed ID: 17161256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals.
    Beck AL; Otto ME; D'Avila LB; Netto FM; Armendaris MK; Sposito AC
    Atherosclerosis; 2012 Jun; 222(2):444-8. PubMed ID: 22554359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial.
    Cardinale D; Ciceri F; Latini R; Franzosi MG; Sandri MT; Civelli M; Cucchi G; Menatti E; Mangiavacchi M; Cavina R; Barbieri E; Gori S; Colombo A; Curigliano G; Salvatici M; Rizzo A; Ghisoni F; Bianchi A; Falci C; Aquilina M; Rocca A; Monopoli A; Milandri C; Rossetti G; Bregni M; Sicuro M; Malossi A; Nassiacos D; Verusio C; Giordano M; Staszewsky L; Barlera S; Nicolis EB; Magnoli M; Masson S; Cipolla CM;
    Eur J Cancer; 2018 May; 94():126-137. PubMed ID: 29567630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).
    Bosch X; Rovira M; Sitges M; Domènech A; Ortiz-Pérez JT; de Caralt TM; Morales-Ruiz M; Perea RJ; Monzó M; Esteve J
    J Am Coll Cardiol; 2013 Jun; 61(23):2355-62. PubMed ID: 23583763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
    Dodos F; Halbsguth T; Erdmann E; Hoppe UC
    Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?
    Radulescu D; Buzdugan E; Ciuleanu TE; Todor N; Stoicescu L
    J BUON; 2013; 18(4):1052-7. PubMed ID: 24344038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
    Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R;
    Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with beta-thalassemia major.
    Karvounis HI; Zaglavara TA; Parharidis GE; Nouskas IG; Hassapopoulou EP; Gemitzis KD; Louridas GE
    Am Heart J; 2001 Feb; 141(2):281. PubMed ID: 11174351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal Myocardial Strain Indices in Children Receiving Anthracycline Chemotherapy.
    Pignatelli RH; Ghazi P; Reddy SC; Thompson P; Cui Q; Castro J; Okcu MF; Jefferies JL
    Pediatr Cardiol; 2015 Dec; 36(8):1610-6. PubMed ID: 26049414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
    Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
    BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of left ventricular systolic dysfunction by tissue Doppler imaging to detect subclinical cardiomyopathy early after anthracycline therapy.
    Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Loperfido F; Biondi-Zoccai G
    Minerva Cardioangiol; 2007 Dec; 55(6):711-20. PubMed ID: 18091640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.
    Elitok A; Oz F; Cizgici AY; Kilic L; Ciftci R; Sen F; Bugra Z; Mercanoglu F; Oncul A; Oflaz H
    Cardiol J; 2014; 21(5):509-15. PubMed ID: 24142687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.